- Study compared adalimumab monotherapy versus adalimumab with methotrexate in moderate to severe plaque psoriasis.
- No significant differences in drug survival, treatment response, or serious adverse events between the two groups.
- Methotrexate did not improve effectiveness or safety despite lower immunogenicity.
- Findings suggest methotrexate may not offer added clinical benefit when used alongside adalimumab for plaque psoriasis.
- Results could inform treatment strategies and prompt further research into alternative approaches.
Source: JAMA Dermatology
